20/20 Biolabs, Inc. (AIDX) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
20/20 Biolabs, Inc. (AIDX) stock forecast summary
Our AI scores 20/20 Biolabs, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
20/20 Biolabs, Inc. is a small-cap company with a market capitalization of $2M.
For AIDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 94 forecast dates between 2026-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 137 forecast dates between 2026-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, AIDX included.
AIDX price chart and AI forecast
How AIDX ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
20/20 Biolabs, Inc. (AIDX) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Testing Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | AIDX | Rank |
|---|---|---|
| Market Cap | $2M | – |
| P/B Ratio | 1.47x | – |
| Book Value/Share | $0.13 | – |
Profitability & Margins
| Metric | AIDX | Rank |
|---|---|---|
| ROE | -342.5% | – |
| ROA | -90.7% | – |
| Net Margin | -263.5% | – |
Financial Health
| Metric | AIDX | Rank |
|---|---|---|
| Current Ratio | 1.99x | – |
| Quick Ratio | 1.95x | – |
| D/E Ratio | 1.83x | – |
| Financial Leverage | 3.78x | – |
| Working Capital | $3M | – |
Income Statement
| Metric | AIDX | Rank |
|---|---|---|
| Net Income | -$6M | – |
Dividend & Shareholder Information
| Metric | AIDX | Rank |
|---|---|---|
| Shares Outstanding | 13M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5M | |
| Cash & Short-term Investments | $5M | 99.2% of assets |
| Accounts Receivable | $290K | 6.3% of assets |
| Inventory | $110K | 2.4% of assets |
| Total Liabilities | $3M | 64.5% of assets |
| Short-term Debt | $2M | 33.1% of assets |
AIDX quarterly financials and insider trading
20/20 Biolabs, Inc. (AIDX) industry peers
Companies classified under the same SEC industry code as 20/20 Biolabs, Inc. (Services-Testing Laboratories): 4 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere AIDX sits on the market map
20/20 Biolabs, Inc. (AIDX) stock news
Loading...
20/20 Biolabs, Inc. (AIDX) stock forecast FAQ
What is the 20/20 Biolabs, Inc. (AIDX) stock forecast?
Our AI scores 20/20 Biolabs, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are 20/20 Biolabs, Inc. stock predictions?
For AIDX, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 15.0%, measured on 94 forecast dates between 2026-03-31 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 28.0%, measured on 137 forecast dates between 2026-03-31 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are 20/20 Biolabs, Inc. forecasts updated?
20/20 Biolabs, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are 20/20 Biolabs, Inc.'s industry peers?
4 issuers in our coverage, AIDX included, share the SEC industry code Services-Testing Laboratories. The largest are: Ul Solutions Inc. (ULS), Neogenomics Inc (NEO), Hypha Labs, Inc. (FUNI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.